These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 1323985)

  • 1. Development of antiviral treatment strategies in murine models.
    Ruprecht RM; Koch JA; Sharma PL; Armany RS
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):997-1011. PubMed ID: 1323985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine models for evaluating antiretroviral therapy.
    Ruprecht RM; Bernard LD; Gama Sosa MA; Sosa MA; Fazely F; Koch J; Sharma PL; Mullaney S
    Cancer Res; 1990 Sep; 50(17 Suppl):5618S-5627S. PubMed ID: 2167158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models for anti-AIDS therapy.
    Koch JA; Ruprecht RM
    Antiviral Res; 1992 Aug; 19(2):81-109. PubMed ID: 1444326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel transgenic mouse model for the in vivo evaluation of anti-human immunodeficiency virus type 1 drugs.
    Mehtali M; Munschy M; Ali-Hadji D; Kieny MP
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):1959-65. PubMed ID: 1493046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Are immunomodulators capable to improve the activity of nucleoside antiretroviral agents?].
    Sinet M; Pocidalo JJ
    Pathol Biol (Paris); 1993 Oct; 41(8 Pt 2):794-8. PubMed ID: 8309723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
    Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
    Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.
    Lapenta C; Santini SM; Proietti E; Rizza P; Logozzi M; Spada M; Parlato S; Fais S; Pitha PM; Belardelli F
    Virology; 1999 Oct; 263(1):78-88. PubMed ID: 10544084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What we know about anti-HIV drugs.
    Treat Rev; 1995 May; (no 18):3-4. PubMed ID: 11362592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agents for treating human immunodeficiency virus infection.
    Acosta EP; Fletcher CV
    Am J Hosp Pharm; 1994 Sep; 51(18):2251-67; quiz 2286-7. PubMed ID: 7801986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anti-HIV-1 therapies and combinations: current data and prospects.
    Eron JJ; Hirsch MS
    AIDS; 1990; 4 Suppl 1():S193-200. PubMed ID: 2152567
    [No Abstract]   [Full Text] [Related]  

  • 11. The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy.
    Boyle MJ; Connors M; Flanigan ME; Geiger SP; Ford H; Baseler M; Adelsberger J; Davey RT; Lane HC
    J Immunol; 1995 Jun; 154(12):6612-23. PubMed ID: 7759895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine models for antiretroviral therapy.
    Ruprecht RM
    Intervirology; 1989; 30 Suppl 1():2-11. PubMed ID: 2540110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses.
    Okuma K; Tanaka R; Ogura T; Ito M; Kumakura S; Yanaka M; Nishizawa M; Sugiura W; Yamamoto N; Tanaka Y
    J Infect Dis; 2008 Jan; 197(1):134-41. PubMed ID: 18171296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment by antiviral drugs of HIV-infected patients].
    Mayaud C
    Rev Pneumol Clin; 1993; 49(2):71-4. PubMed ID: 8272744
    [No Abstract]   [Full Text] [Related]  

  • 15. New developments in antiretroviral drug therapy for HIV infection.
    Johnson VA
    AIDS Clin Rev; 1992; ():69-104. PubMed ID: 1318738
    [No Abstract]   [Full Text] [Related]  

  • 16. A short hairpin loop-structured oligodeoxynucleotide targeting the virion-associated RNase H of HIV inhibits HIV production in cell culture and in huPBL-SCID mice.
    Heinrich J; Schols D; Moelling K
    Intervirology; 2012; 55(3):242-6. PubMed ID: 21576910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner.
    Shih CC; Kaneshima H; Rabin L; Namikawa R; Sager P; McGowan J; McCune JM
    J Infect Dis; 1991 Mar; 163(3):625-7. PubMed ID: 1995734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.
    Kosaka K; Hiraga N; Imamura M; Yoshimi S; Murakami E; Nakahara T; Honda Y; Ono A; Kawaoka T; Tsuge M; Abe H; Hayes CN; Miki D; Aikata H; Ochi H; Ishida Y; Tateno C; Yoshizato K; Sasaki T; Chayama K
    Biochem Biophys Res Commun; 2013 Nov; 441(1):230-5. PubMed ID: 24140055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiviral strategies in the replication of human immunodeficiency virus].
    Wainberg MA; Bour S; Geleziunas R; Bentwich Z
    Union Med Can; 1992; 121(5):307-9, 312-4. PubMed ID: 1279875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cyclophosphamide, total body irradiation, and zidovudine on retrovirus proliferation and disease progression in murine AIDS.
    Klinman DM; Krieg A; Conover J; Ussery MA; Black PL
    AIDS Res Hum Retroviruses; 1992 Jan; 8(1):101-6. PubMed ID: 1310603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.